Inspire Medical Systems, Inc.
INSPInspire Medical Systems, Inc. develops and commercializes medical devices for the treatment of sleep apnea. The company's flagship device, the Inspire Therapy system, uses neurostimulation technology to stimulate the hypoglossal nerve, helping to keep the airway open during sleep. Founded in 2007 and headquartered in Minneapolis, Minnesota, Inspire aims to provide an alternative to traditional sleep apnea treatments such as CPAP machines.
Company News
A securities class action lawsuit has been filed against Inspire Medical Systems for alleged securities fraud related to the launch of their Inspire V medical device, which resulted in significant stock price decline after revealing launch delays and poor demand.
Nyxoah received FDA Pre-Market Approval for its GENEO system to treat obstructive sleep apnea, launching a 50-person commercial team targeting high-volume U.S. implanting centers with 73.8% year-over-year revenue growth.
Inspire Medical Systems has received CE mark certification for its Inspire therapy under the European Union's Medical Device Regulation (EU MDR), which is a significant milestone for the company's expansion in the global obstructive sleep apnea treatment market.
Mizuho Securities reduced its price target for Inspire Medical Systems (INSP) from $250 to $200, citing a valuation change after the SURMOUNT-OSA study results. However, the firm maintained an Outperform rating on the company's shares.
In the latest quarter, 6 analysts provided ratings for Inspire Medical Systems (NYSE:INSP), showcasing a mix of bullish and bearish perspectives. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat...
